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Analysis of Volatile Organic Compounds of Bacterial Origin in
Chronic Gastrointestinal Diseases
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Background: The aim of this study was to determine whether volatile organic compounds (VOCs) present in the headspace of feces could be used to
diagnose or distinguish between chronic diseases of the gastrointestinal tract and apparently healthy volunteers.
Methods: A total of 87 people were recruited, divided between 4 categories: healthy volunteers (n ¼ 19), Crohn’s disease (n ¼ 22), ulcerative colitis
(n ¼ 20), and irritable bowel syndrome (n ¼ 26). They each supplied fecal samples before, and except for the healthy volunteers, after treatment. Fecal
samples were incubated in a sample bag with added puriﬁed air at 408C and headspace samples were taken and concentrated on thermal sorption tubes.
Gas chromatography–mass spectrometry then desorbed and analyzed these. The concentrations of a selection of high-abundance compounds were
determined and assessed for differences in concentration between the groups.
Results: Crohn’s disease samples showed signiﬁcant elevations in the concentrations of ester and alcohol derivates of short-chain fatty acids and indole
compared with the other groups; indole and phenol were elevated in ulcerative colitis and irritable bowel syndrome but not at a statistically signiﬁcant
level. After treatment, the levels of many of the VOCs were signiﬁcantly reduced and were more similar to those concentrations in healthy controls.
Conclusions: The abundance of a number of VOCs in feces differs markedly between Crohn’s disease and other gastrointestinal conditions. Following
treatment, the VOC proﬁle is altered to more closely resemble that of healthy volunteers.
(Inﬂamm Bowel Dis 2013;0:1–10)
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C hronic diseases of the intestinal tract present considerablepractical difﬁculties, both in terms of diagnosis and of health
economics. Irritable bowel syndrome (IBS) is the most common
gastrointestinal (GI) disorder encountered in the Western world,
affecting perhaps 15% of the population yet remains a diagnosis of
exclusion. A series of expensive and sometimes unpleasant inves-
tigations, including analyses of blood, urine and feces, radiology,
and endoscopy, must be performed to exclude other more danger-
ous diseases, before the diagnosis can be accepted. Inﬂammatory
bowel disease (IBD) is less common but presents with symptoms
of abdominal pain and diarrhea that might be very similar to those
of IBS. Diverticular disease and carcinoma of the colon must also
be excluded.
In recent years, growing attention has been focused on the
role of the intestinal microbiota in the pathogenesis of chronic GI
diseases.1 The intestinal microbiota, however, is very complex,
with 1011–1012 bacteria per gram of AU5contents present in the
colon.2 A report from the MetaHIT (Metagenomics of the Human
Intestinal Tract) project estimated that a cohort of 124 European
volunteers harbored a total some of 1150 distinct bacterial species,
with each individual having at least 160.3 As yet, no speciﬁc
pathogen has been shown to be associated with any of these
disorders. The microbiota is known, however, to be abnormal in
both IBS and IBD, with a reduction in the number of Actino-
bacteria and Firmicutes and overgrowth by Proteobacteria.4–6
The microbiota has been shown to be the subject of
immune attack in IBD.7 Over 80% of fecal microorganisms are
coated with immunoglobulin, but these numbers fall rapidly in
patients receiving successful treatment.8 A role for the microbiota
has also been shown in IBS with abnormal bacterial fermentation,
leading to increased excretion of hydrogen. Correction of such
fermentation whether by antibiotics or diet leads to amelioration
of symptoms,9–11 and abnormal fermentation is now believed to
underlie reports of food intolerances in some cases of IBS.12,13
Progress in chemometrics means that it is now possible to
analyze complex mixtures of chemical compounds in biological
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ﬂuids.14 There is strong anecdotal evidence that feces from patients
with GI disease have an abnormal smell, moreover, that different
malodors are indicative of particular conditions. It has long been
known that bacteria emit volatile organic compounds (VOCs) as
by-products of metabolism. Kuzma et al15 demonstrated the produc-
tion of isoprene from gram-positive and gram-negative species,
whereas later studies showed, for example, the production of hydro-
gen cyanide from Pseudomonas aeruginosa,16,17 methanethiol and
ammonia from methionine in Clostridium sporogenes, and indole
and phenol as products of aromatic amino acid breakdown.18 A
number of reports have suggested that bacteria may be distinguished
by means of their individual VOC proﬁles and that it might prove
possible to develop this approach for diagnostic purposes.19–21 Sev-
eral studies that have used a variety of analytical approaches to
differentiate between infected and noninfected samples in a range
of biological matrices such as urine,22 sputum,23 and feces supported
these ﬁndings.24
This suggests that different patterns of VOC production in
fecal samples may indicate variations in the gut microbiota, which in
turn are indicative of speciﬁc disease processes. If so, determination
of fecal VOC proﬁles could offer a route to the rapid and noninvasive
diagnosis of a range of GI diseases. Studies of patients with
ulcerative colitis (UC), Clostridium difﬁcile, and Campylobacter
jejuni infections, which have yielded encouraging results, supported
this idea.25,26 These studies used solid-phase extraction of fecal head-
space VOCs followed by analysis using gas chromatography–mass
spectrometry to establish presence/absence scores for over 100 vol-
atile species and demonstrated that different patterns of VOCs were
associated with each condition investigated.
In this study, we have extended this approach by using
pumped headspace sampling onto thermal desorption (TD) tubes,
which has allowed us to make quantitative estimations of the
concentration of VOCs evolved from human fecal samples. We
have determined VOC concentration in patients with clinical
diagnoses of UC, Crohn’s disease (CD), or IBS before and after
treatment and in a group of healthy controls. Our hypothesis is
that treatment should, and ameliorating symptoms, result in a nor-
malization of the fecal headspace VOC proﬁle.
MATERIALS AND METHODS
Patients and Sample Collection
Patients and healthy volunteers were recruited at the Depart-
ment of Gastroenterology, Addenbrooke’s Hospital, Cambridge,
United Kingdom. The diagnosis of CD, UC, or IBS was made by
standard diagnostic criteria. All patients had symptoms of active
relapse of disease. None had received previous dietary treatment,
but some were taking medication including 5-aminosalicylic acid
compounds and or azathioprine, which was insufﬁcient to control
their symptoms. Antibiotic usage in the previous 6 weeks was an
exclusion criterion. A numerical code identiﬁed subjects and their
diagnosis, and the diagnosis was not revealed to the analysts until all
specimens had been tested. All signed informed consent to the
procedures. Nonfasting morning samples of feces were obtained
from each subject (pretreatment samples). Numbers of males and
females in each of the disease and control groups are given in
Table T11.
TABLE 1. Numbers of Volunteers in Disease and
Control Groups
Group Males Females
Control 11 8
IBS 4 22
UC 12 8
CD 8 14
FIGURE 1. Part of a total ion chromatogram alignment for control and
pretreatment disease groups, illustrating the visual inspection method
for generating a list of candidate compounds for statistical analysis.
Some compounds exhibiting differences in abundance between groups
are indicated. The total duration of the analysis was 30 minutes, but for
clarity, only the central portion (13–17 minutes) of the overall chro-
matogram is shown. Horizontal scale ¼ time; vertical scale ¼ relative
abundance.
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Treatment varied according to diagnostic category. Those
with Crohn’s disease were offered 2 weeks of treatment with an
elemental feed (E028 Extra; Nutricia, Liverpool, United Kingdom).27
Patients with UC were treated with oral corticosteroids and
5-aminosalicylic acid derivatives and those with IBS were given
exclusion diets.28 In each case, patients returned to the hospital
after 2 weeks of treatment and a fecal sample was collected
(posttreatment samples). Healthy control subjects attended the
department on a single occasion for collection of a similar spec-
imen. Volunteers unable to provide a fecal specimen at initial
interview were given a sample pot to take away and instructed to
provide a stool specimen within 48 hours and not to change their
treatment in any way until this had been provided. Samples were
delivered to the hospital on the same day as they were passed
with a maximum delay before freezing of 4 hours. Samples were
stored at 2408C until transfer to the laboratory.29 Ethical per-
mission for this study was granted by the Leeds West Local
Ethical Committee (Ref. 07/Q1205/39).
Sample Preparation
Samples were transferred to the laboratory packed in dry
ice inside insulated containers and on arrival were stored
at 2808C until analyzed. Gas sampling bags for headspace anal-
ysis were prepared from 65-mm-wide Nalophan NA tube cut to
500 mm lengths. A 70 mm length of 6-mm-diameter polypro-
pylene tubing bearing a 1/400 Swagelok ﬁtting was secured to one
end using nylon ties. Each sample was defrosted at room tem-
perature before analysis, a 5-mL aliquot being added to the open
end of the bag using the scoop provided with the sample con-
tainer. The bag was then sealed using nylon ties, and the bag was
ﬁlled with hydrocarbon-free air. Bags containing samples were
incubated at 408C for 10 minutes before 500 mL of the head-
space gas was pumped (100 mL/min for 5 minutes using a por-
table air pump) over TD tubes prepacked with 50% Carbotrap
TABLE 2. Candidate Compounds for Statistical
Analysis Selected as Described in Methods
Selection Method Name CAS No. RT, min
Most abundant Acetone 67-64-1 7.23
Propanoic acid 79-09-4 13.75
Butanoic acid 107-92-6 15.86
Published data 1-Propanol 71-23-8 9.06
Propanoic acid, ethyl ester 105-37-3 12.50
Butanoic acid, methyl ester 623-42-7 12.87
Butanoic acid, ethyl ester 105-54-4 14.85
P-cresol 106-44-5 22.82
Indole 120-72-9 29.49
Dimethyl disulphide 624-92-0 13.90
Visual inspection 1-Butanol 71-36-3 11.98
Butanoic acid, 3-methyl 503-74-2 17.08
RTs indicated are typical.
CAS number, Chemical Abstracts Service Reference Number; RT, retention time.
TABLE 3. Concentrations of VOCs in Fecal Headspace From Healthy Controls and Volunteers Diagnosed With CD,
UC, and IBS Before Prescribed Treatment
Compound
VOC Concentration, ng/L
Median (Lower Quartile, Upper Quartile)
Control CD UC IBS P
Acetone 142 (21, 336) 83 (38, 253) 121 (80, 241) 68 (36, 151) 0.594
Propanoic acid 6 (0, 55) 183 (0, 354) 32 (0, 353) 80 (0, 303) 0.474
Butanoic acid 33 (3, 202) 1074 (22, 1521) 169 (4, 1339) 628 (83, 1362) 0.043a
1-Propanol 13 (0, 33) 281 (38, 897) 64 (7, 659) 33 (4, 62) 0.003a
Propanoic acid, ethyl ester 0 (0, 0) 30 (1, 181) 0 (0, 60) 0 (0, 4) 0.000a
Butanoic acid, methyl ester 0 (0, 3) 30 (6, 114) 7 (0, 79) 11 (0, 33) 0.015a
Butanoic acid, ethyl ester 0 (0, 1) 46 (4, 376) 22 (0, 324) 1 (0, 42) 0.006a
P-cresol 122 (50, 433) 499 (115, 1217) 221 (117, 960) 213 (18, 587) 0.155
Indole 9 (3, 34) 127 (56, 587) 27 (13, 163) 41 (8, 117) 0.001a
Dimethyl disulphide 30 (4, 71) 114 (58, 870) 71 (27, 143) 57 (11, 412) 0.075
1-Butanol 9 (0, 39) 142 (76, 406) 25 (3, 554) 57 (21, 89) 0.004a
Butanoic acid, 3-methyl 7 (0, 48) 141 (69, 406) 28 (1, 962) 68 (7, 590) 0.035a
Phenol 9 (3, 35) 68 (21, 188) 21 (5, 180) 13 (5, 22) 0.021a
Median and upper and lower quartile values are shown; Kruskal–Wallis 1-way analysis of variance examined differences between groups.
aP , 0.05 being considered signiﬁcant.
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and 50% Tenax (Markes International Ltd, Llantrisant, United
Kingdom).
Laboratory Analysis
An internal standard solution comprising 50 ngAU6 d8-toluene
(Supelco Cat No. 48,593) in methanol was added to each tube
according to the manufacturer’s instructions (Markes International
Ltd). Automated thermal desorption–gas chromatography–mass
spectrometry analyzed headspace samples. A PerkinElmer system
was used for analysis, combining a TurboMass MS 4.1, Autosystem
XL GC, and Automatic Thermal Desorption system (ATD 400;
PerkinElmer, Wellesley, MA). The carrier gas wasAU7 CP-grade helium
(BOC Gases, Guildford, United Kingdom) passed through a com-
bined trap for removal of hydrocarbons, oxygen, and water vapor.
A wall-coated Zebron ZB624 chromatographic column was used
(Phenomenex, Torrance, CA), with dimensions 30 · 0.4 · 0.25 mm
(internal diameter), the liquid phase comprising a 0.25-mm layer of
6% cyanopropylphenyl and 94% methylpolysiloxane.
Thermal desorption tubes were initially purged for 2 minutes
to remove air and water vapor and then desorbed for 5 minutes at
3008C. The automatic thermal desorption valve temperature was set
to 1808C, and TD tubes were desorbed onto the secondary cold
trap, which was initially maintained at 308C. Once desorption was
complete, the secondary trap was heated to 3208C using the fastest
available heating rate and then maintained for 5 minutes, whereas
the efﬂuent was transferred to the gas chromatography through
a transfer line heated to 2108C. The gas chromatography oven
was maintained at 508C for 4 minutes after injection and then
raised at a rate of 108C/min until reaching 2208C and then held
for 9 minutes. A heated line held at 2408C to the mass spectrom-
eter transferred the eluted products where the compounds were
subjected to electron ionization. Full scan mode was selected
with mass to charge ratios from 33 to 350 m/z with a scan time
of 0.3-second and 0.1-second interscan delay to produce a total
ion chromatogram.
Data Analysis
Compound identiﬁcation was achieved using Automated
Mass Spectral Deconvolution and Identiﬁcation (AMDIS version
2.62) software and the National Institute of Standards and
Technology mass spectral library. Quantiﬁcation was achieved
by comparing the area of each compound peak with the peak area
associated with the known amount of d8-toluene.
In any given fecal headspace sample, AMDIS would
identify from (approximately) 100 to 300 different compounds
and it was therefore found necessary to select a subset of those we
observed to render statistical analysis tractable. Three approaches
were followed to provide a list of what we have termed “candidate
compounds.” The list comprised ﬁrst compounds that appeared to
be most abundant from inspection of the results obtained using
AMDIS; second, compounds that appeared to discriminate
between patient groups by visual inspection of a subset of pre-
treatment sample chromatograms (F1 Fig. 1 for an example); and
third, compounds selected on the basis of published work. For
the latter approach, an initial generic list was made including
short-chain fatty acids (SCFAs) and their derivatives, phenolic
compounds and indole, and sulphides.30–32 This list was then
reﬁned according to publications dealing more explicitly with
VOC proﬁles in GI disease.25,33,34 A ﬁnal list of 13 compounds
was obtained in this way.
The frequency distributions for all compounds were found
to be highly skewed with a proportion of nondetects; therefore,
a nonparametric statistical approach was adopted that is described
in detail in the Results section.
ETHICAL CONSIDERATIONS
The Leeds West Local Ethical Committee granted ethical
permission for this study (Ref. 07/Q1205/39).
FIGURE 2. Box-and-whisker plots of the concentration of butanoic
acid methyl ester in patients with GI disease and healthy controls,
before prescribed treatment. The boxes indicate the lower and upper
quartiles, the transverse bars the median, and the whiskers indicate
the range. A, Whole data range. B, Expanded vertical scale to show
relative locations of medians and quartiles.
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RESULTS
TableT2 2 lists the 13 candidate compounds according to their
method of selection and typical gas chromatography retention
times. Statistical analysis was carried out using STATISTICA
version 10 (Statsoft, Inc, Tulsa, OK).
Concentrations of each candidate compound from the
control group and volunteers with CD, UC, and IBS obtained
before treatment were compared using a Kruskal–Wallis 1-way
analysis of variance. The comparison of the control and disease
groups before treatment is shown inT3 Table 3.
Because of the highly skewed frequency distribution
observed for all compounds, median and upper and lower quartile
values are listed. Statistically signiﬁcant differences were
observed for 8 of the 13 candidate compounds with at least 1
compound found to be signiﬁcant from each method of selection.
Where signiﬁcant differences did occur, they were always
associated with elevated concentrations of the relevant compound
in the disease groups relative to the controls. The largest
elevations were associated with the CD group.
Despite the statistically signiﬁcant differences between
groups, there was considerable overlap in the values of the
measured concentrations and all compounds exhibited a wide
dynamic range in all groups including the controls. This is
illustrated inF2 Figure 2 for a representative compound, butanoic
acid methyl ester. The wide dynamic range of the observed con-
centrations necessitated plotting the data on 2 different scales to
allow both the whole range to be shown and the relative locations
of medians and quartiles.
Table T44 shows the comparison of the control and disease
groups following appropriate treatment regimens as described in
the Methods section. Generally, a striking reduction in the con-
centrations of the candidate compounds was observed in the dis-
ease groups, and this was reﬂected in there being fewer
statistically signiﬁcant differences among all groups (controls
and patients) assessed using the Kruskal–Wallis test. The only
signiﬁcant difference persisting was in propanoic acid ethyl ester
(P ¼ 0.003), and even here, the observed concentrations in the
disease groups were markedly lower than those observed pre
treatment. The effect of treatment on a representative compound,
butanoic methyl ester, is illustrated in F3Figure 3. This has been
plotted to the same scale as Figure 2 to facilitate comparison of
pretreatment and posttreatment data. As before, 2 plots are pro-
vided to take account of the wide dynamic range of the data.
Where statistically signiﬁcant differences were observed,
post hoc tests were carried out using the z statistic described by
Siegel and Castellan35 to establish the existence of signiﬁcant
differences between each pair of subject groups. The results of
this analysis are presented in T5Table 5, which shows the value of
the z statistic and associated P value for each pairwise compari-
son. It is notable that 1 pairwise comparison was found to be
statistically signiﬁcant for each compound; this was invariably
between the control group and CD patients.
One limitation of this analysis is that it was not possible to
obtain both pretreatment and posttreatment samples from all
volunteers. Consequently, the data could be considered to have
been obtained in groups that are at least partly independent and
TABLE 4. Concentrations of VOCs in Fecal Headspace From Healthy Controls and Volunteers Diagnosed With CD,
UC, and IBS Following Prescribed Treatment
Compound
VOC Concentration, ng/L
Median (Lower Quartile, Upper Quartile)
Control CD UC IBS P
Acetone 142 (21, 336) 80 (50, 104) 59 (38, 123) 100 (73, 146) 0.498
Propanoic acid 6 (0, 55) 14 (0, 84) 62 (0, 220) 175 (0, 529) 0.432
Butanoic acid 33 (3202) 53 (0, 104) 203 (7, 778) 111 (5, 1445) 0.348
1-Propanol 13 (0, 33) 146 (6, 661) 10 (5, 101) 20 (6, 62) 0.199
Propanoic acid, ethyl ester 0 (0, 0) 2 (0, 15) 0 (0, 0) 0 (0, 0) 0.003a
Butanoic acid, methyl ester 0 (0, 3) 1 (0, 5) 0 (0, 1) 4 (0, 21) 0.058
Butanoic acid, ethyl ester 0 (0, 1) 2 (0, 21) 0 (0, 0) 0 (0, 0) 0.058
P-cresol 122 (20, 433) 505 (213, 1234) 477 (80, 1309) 301 (112, 854) 0.203
Indole 9 (3, 34) 32 (0, 128) 13 (5, 142) 39 (3, 110) 0.723
Dimethyl disulphide 30 (4, 71) 77 (20, 149) 43 (23, 133) 130 (20, 190) 0.408
1-Butanol 9 (0, 39) 86 (6, 204) 7 (2, 151) 39 (0, 265) 0.496
Butanoic acid, 3-methyl 7 (0, 48) 6 (0, 45) 2 (0, 243) 129 (2, 552) 0.171
Phenol 9 (3, 35) 31 (16, 181) 14 (5, 21) 11 (5, 28) 0.092
Median and upper and lower quartile values are shown; Kruskal–Wallis 1-way analysis of variance examined differences between groups.
aP , 0.05 being considered signiﬁcant.
Inﬂamm Bowel Dis  Volume 0, Number 0, Month 2013 Analysis of Volatile Organic Compounds
www.ibdjournal.org | 5
hence to have arisen by chance. A further analysis was therefore
carried out using the Wilcoxon signed-rank test to compare VOC
concentrations in pretreatment and posttreatment samples for
those cases where paired data were available. The numbers of
paired samples available were 17, 7, and 16 for CD, UC, and IBS
groups, respectively. The results are shown inT6 Table 6. It will be
noted that the number of paired samples (“n” in Table 6) differs
by compound within each volunteer group. This arose because of
the difﬁculty in obtaining positive identiﬁcation of compounds
when present at very low concentration, where the signal-to-noise
ratio was relatively poor. In some cases, a peak was discernible at
the appropriate retention time for a given compound but positive
identiﬁcation could be made neither by AMDIS nor by visual
inspection of the mass spectrum. In these cases, data were
recorded as missing; it being considered less likely to bias the
results than recording a nondetect or the concentration calculated
on the dubious peak.
The results are broadly consistent with the unpaired
analyses (Tables 3–5). Of the 13 candidate compounds, 7 were
found to be signiﬁcantly reduced following treatment in the CD
group, with no signiﬁcant differences observed in either UC or
IBS. Of these 7, 6 were also found to be statistically signiﬁcant in
the unpaired analysis of pretreatment data (Table 3). Three com-
pounds, butanoic acid methyl ester, indole, and phenol, were
signiﬁcant in the unpaired analysis but not in the paired analysis.
Conversely, a signiﬁcant reduction in propanoic acid was found in
the paired analysis, but this compound was not signiﬁcantly dif-
ferent between groups in the unpaired analysis. A particularly
striking difference was observed in butanoic acid concentration
in CD patients from a median of 1075 to 1 ng/L.
DISCUSSION
We have used pumped sampling onto TD tubes to
determine the concentrations of a range of VOCs in the headspace
of fecal samples from patients with CD, UC, or IBS and also
a group of healthy control volunteers. As far as we are aware, this
is the ﬁrst report in which quantiﬁcation of VOCs in fecal
headspace has been attempted and also the ﬁrst to examine the
effects of prescribed treatment. Although a fecal headspace
sample can yield more than a hundred different volatile species,
we selected a relatively small number (13, decided empirically) of
candidate compounds to render statistical analysis tractable.
Selection was carried out, with no a priori hypothesis, on the
basis of relative abundance, indications from previous studies, and
inspection of a small subset of our own data. This was a highly
empirical method but proved to be effective. We also considered
using a multivariate approach to analyze these data, but this was
precluded for a variety of reasons, particularly the proportion of
missing data and the highly skewed frequency distribution of all
variables, which together with the presence of a number of
nondetects made it impossible to normalize the data by trans-
formation. The compounds selected can be considered as falling
into 3 broad categories: SCFAs and their derivatives (propanoic
and butanoic acids and their corresponding alcohols, esters, and
branched derivatives), products of protein metabolism (indole,
phenol, and para-cresol), and other common bacterial metabolites
(acetone and dimethyl disulphide).
The concentrations of propanoic and butanoic acids were
highest in the CD group, although statistically signiﬁcant only for
butanoic acid. SCFAs originate largely from bacterial fermenta-
tion of polysaccharides and dietary ﬁber, although they can also
be produced by the metabolism of polypeptides from dietary or
endogenous sources such as bleeding, mucins, or sloughed cells.31
SCFAs are considered to have beneﬁcial effects on the human
colon. They can act as a source of energy, affect colonic mucosal
growth, promote the absorption of sodium and water, and mitigate
against diarrhea. Butanoic acid is thought to have a protective
FIGURE 3. Box-and-whisker plots of the concentration of butanoic acid
methyl ester in patients with GI disease and healthy controls, following
prescribed treatment. The boxes indicate the lower and upper quartiles,
the transverse bars indicate the median, and the whiskers indicate the
range. A, Whole data range. B, Expanded vertical scale to show relative
locations of medians and quartiles. Plotted to the same scale as Figure 2
to facilitate comparison with pretreatment results.
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effect against colonic cancer, but the evidence for this is equivocal.36
Incubation of fresh stool with labeled butanoic acid has demon-
strated the production of a range of esters and also 1-butanol,25
and it is likely that homologous series of metabolites are produced
from other SCFAs. Much less is known about the physiological
effects of these derivatives, although it has been suggested that
1-propanol may be damaging to the gut.25 There is also evidence
that ethyl esters of fatty acids may exert a toxic effect by inducing
mitochondrial dysfunction.37,38 Although these ﬁndings pertain to
derivatives of long-chain fatty acids, they are nonetheless striking in
view of the high concentration of fatty acid esters observed, espe-
cially in the case of CD.
In contrast to SFCAs, the products of amino acid fermen-
tation, indole, phenol, and p-cresol are generally considered to be
toxic to the gut. We detected statistically signiﬁcant elevations in
the concentration of indole and phenol in CD patients compared
with controls. Concentrations were also higher in the UC and
irritable bowel disease groups than in the controls but were not
found to be signiﬁcant in post hoc tests between pairs of groups
(Table 5). Para-cresol was widely detected in fecal headspace
samples with the highest concentrations observed in CD;
however, there was no statistically signiﬁcant difference between
groups.
No signiﬁcant differences were found in acetone concen-
tration. This might be expected because acetone was selected as
a candidate compound on the basis of high relative abundance and
is a product of lipolysis by many organisms including bacteria.
Similarly, dimethyl disulphide is produced as a result of the
bacterial metabolism of sulfur-containing compounds
(e.g., proteins containing disulphide bonds) and is one of the
compounds that contribute to the characteristic odor of feces.32
The absence of any signiﬁcant changes in these general markers
of bacterial metabolism suggests that our ﬁndings reﬂect changes
in the balance of the gut microbiota rather than a change in the
overall number of bacteria or increase in metabolic activity. This
also provides some reassurance that our results are not signiﬁ-
cantly affected by variations in sample consistency or water
content.
The use of gas chromatography as a method for identiﬁ-
cation of bacteria is by no means new. As early as 1967, Lewis
et al39 observed signiﬁcant differences in SCFA production
between different species of Clostridium and subsequent studies
TABLE 5. Pairwise Comparisons Between Groups Examined Using the Z Statistic of Siegel and Castellan
Post Hoc Comparisons Between Groups (Z Value, P)
Compound
Control
Versus CD
Control
Versus UC
Control
Versus IBS
CD
Versus UC
CD V
ersus IBS
UC
Versus IBS
Pretreatment data
Butanoic acid 2.71 1.27 2.14 1.37 0.50 0.85
0.041a 1.000 0.194 1.000 1.000 1.000
1-Propanol 3.56 1.85 0.85 1.52 2.39 0.89
0.002a 0.387 1.000 0.767 0.102 1.000
Propanoic acid, ethyl ester 3.93 2.39 1.72 1.38 2.16 0.70
0.001a 0.102 0.511 1.000 0.183 1.000
Butanoic acid, methyl ester 3.16 1.83 1.73 1.03 1.42 0.25
0.009a 0.403 0.506 1.000 0.936 1.000
Butanoic acid, ethyl ester 3.26 2.22 1.46 0.63 1.90 0.98
0.007a 0.160 0.858 1.000 0.345 1.000
Indole 4.05 1.82 1.80 2.18 2.13 0.01
0.000a 0.412 0.429 0.178 0.202 1.000
1-Butanol 3.60 1.58 1.55 1.86 2.08 0.11
0.002a 0.683 0.734 0.378 0.224 1.000
Butanoic acid, 3-methyl 2.88 1.39 2.00 1.21 0.82 0.45
0.024a 0.990 0.273 1.000 1.000 1.000
Phenol 2.68 1.38 0.21 1.11 2.55 1.21
0.044a 1.000 1.000 1.000 0.064 1.000
Posttreatment data
Propanoic acid, ethyl ester 2.49 0.488 0.753 1.71 1.92 0.144
0.076a 1.000 1.000 0.518 0.326 1.000
These analyses were completed post hoc for those compounds for which the initial Kruskal–Wallis test produced a statistically signiﬁcant result.
aDifferences were considered statistically signiﬁcant.
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extended this to other clinically relevant bacteria and the direct
analysis of clinical material.40–42 It is only more recently, how-
ever, that the relatively easy availability of automated mass spec-
trometry techniques has allowed this approach to be fully
exploited. To date, there have appeared only a limited number
of reports of volatile proﬁling in fecal samples. Garner et al25 used
solid-phase microextraction and gas chromatography–mass spec-
trometry to demonstrate the diagnostic potential of fecal VOCs in
UC and C. difﬁcile and C. jejuni infection. It is difﬁcult to com-
pare these results with the current data because they are expressed
in terms of presence/absence scores for each of a very wide range
of compounds that were then analyzed using a multivariate
approach. Although highly effective in separating the groups in
their study, this method makes it difﬁcult to ascribe the observed
differences to particular compounds. Our use of pumped TD tubes
has enabled us to estimate the quantities of VOCs produced by
fecal samples, and in fact, all those in the candidate compound list
were widely observed in samples from all the groups in our study.
De Preter et al34 have developed a method employing purge-and-
trap sampling that allows quantiﬁcation of fecal headspace VOCs,
although as far as we are aware at the present time, only data from
a group of healthy volunteers have been reported.
We found pronounced differences in the median concen-
trations of a number of VOCs in the headspace of feces of patients
with GI disease compared with healthy control volunteers, which
suggests that this method has potential diagnostic value. Despite
the large magnitude of the differences, however, the data occupy
a wide dynamic range and there remains considerable overlap in
the values observed in each group, as illustrated in Figure 2 for
butanoic acid methyl ester. It therefore seems likely that a panel
comprising several marker compounds would be required to pro-
vide sufﬁcient discrimination for the diagnosis of individual cases.
Of the compounds determined in this study, our results indicate
that the best discrimination might be provided by propanoic acid
ethyl ester, butanoic acid methyl ester, 1-propanol, 1-butanol, and
possibly also indole.
A potential limitation on the practical employment of this
method is that statistically signiﬁcant differences in VOC concen-
tration were found only between the CD and control groups
(Table 5), which suggests that differential diagnosis of Crohn’s
disease, UC, and IBS might require some reﬁnement. Nonetheless,
there persist large relative differences in the median concentrations
of some compounds between the disease groups, notably propanoic
acid, 1-propanol, and butanoic acid ethyl ester (Table 3). This area
merits further investigation, possibly using modiﬁed sampling and
analytical protocols to minimize methodological variability, and the
use of multivariate data analysis techniques to cope with the high
dimensionality of the resultant data sets.
Our results clearly show signiﬁcant differences in VOC
concentration between the control and disease groups, which reﬂect
changes in the gut microbiota found in these conditions. It is
however impossible in the current state of knowledge to relate the
two in detail. It is known that in IBD, Actinobacteria and
Firmicutes are relatively inactive or dormant, whereas there is an
expansion of the Proteobacteria, especially Escherichia coli, Cam-
pylobacter concisus, and Helicobacter spp.5,6 However, changes in
TABLE 6. Comparison of Paired Pretreatment and Posttreatment Fecal Headspace VOC Concentrations Using the
Wilcoxon Signed-Rank Test
Paired Comparisons Between Pretreatment and Posttreatment VOC Concentrations
Median Pretreatment, Median Posttreatment (n, P)
Compound CD UC IBS
Acetone 64–83 (16, 0.352) 118–65 (7, 0.735) 84–109 (14, 0.300)
Propanoic acid 125–18 (14, 0.048aAU9 ) 0–1 (5, 0.345) 21–286 (13, 0.064)
Butanoic acid 1074–1 (15, 0.002a) 4–10 (7, 0.398) 362–576 (13, 0.807)
1-Propanol 281–123 (15, 0.041a) 0–9 (7, 1.000) 46–37 (10, 0.386)
Propanoic acid, ethyl ester 49–1 (13, 0.002a) — 0–0 (6, 0.249)
Butanoic acid, methyl ester 14–0 (12, 0.084) 0–1 (2, 0.655) 18–14 (12, 1.000)
Butanoic acid, ethyl ester 68–1 (15, 0.011a) 0–0 (2, 0.655) 2–0 (8, 0.123)
P-cresol 711–530 (15, 0.820) 29–85 (7, 0.612) 426–424 (11, 0.534)
Indole 127–44 (14, 0.177) 25–13 (7, 0.499) 41–56 (12, 0.754)
Dimethyl disulphide 67–64 (12, 0.388) 78–43 (6, 0.388) 46–164 (13, 0.753)
1-Butanol 142–86 (13, 0.011a) 6–12 (6, 0.917) 58–43 (14, 0.551)
Butanoic acid, 3-methyl 147–28 (14, 0.026a) 5–123 (6, 0.753) 104–276 (14, 0.638)
Phenol 84–24 (13, 0.133) 94–9 (6, 0.345) 12–9 (14, 0.975)
Em dash indicates insufﬁcient paired data to permit comparison.
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the composition of the bacterial population do not necessarily
reﬂect overall metabolic activity, and it has in fact been suggested
that species at lowest abundance might in fact be metabolically the
most active.43 An added complication of uncertain effect is the
presence of relatively small numbers of viruses and fungi. It there-
fore seems unlikely that changes in abundance of individual species
will relate directly to the observed changes in VOC proﬁle. How-
ever, our results are consistent with the results of earlier studies by
Garner et al,25 who demonstrated the production of SCFAs and
their derivatives from fecal cultures obtained from IBD patients,
and by van Nuenen et al,33 who found increased production of
short-chain and branched-chain fatty acids by feces from IBD pa-
tients compared with healthy individuals when cultured in an
in vitro model of the large intestine.
These differences are largely normalized following treat-
ment, when the VOC proﬁle more closely resembles that found in
the controls (Table 4), indicating reestablishment of a relatively
normal microbiota. Following treatment, the overall pattern was
of large reductions in the concentration of VOCs, with particularly
striking changes in the CD group for butanoic acid (1037–54 ng/L),
propanoic acid ethyl ester (26–2 ng/L), and butanoic acid ethyl
ester (30–1 ng/L). However, some compounds did exhibit increased
concentrations following treatment, almost entirely conﬁned to the
UC and IBS groups. Although none of these differences were
statistically signiﬁcant, this observation merits further study.
Analysis of paired data produced broadly similar results
with statistically signiﬁcant reductions in a range of VOCs
observed in the CD patients but with some sizable nonsigniﬁcant
increases in some compounds following treatment: The elevation
in propanoic acid from 21 to 286 ng/L after treatment for IBS is
particularly notable. These data suggest that fecal VOC analysis
might provide a suitable means for monitoring disease process
and efﬁcacy of treatment in patients with established primary
diagnoses. For this to be viable, concentrations of the relevant
compounds would need to be measured and assessed on an
individual basis. Clearly, however, the sampling, analysis, and
interpretation of such data would need signiﬁcant development to
be useful for clinical practice; however, it is envisaged that with
developments in gas sensing, it is feasible that a small number of
targeted compounds could be readily measured in the headspace
of freshly voided feces in a purpose built device. This would
greatly reduce the complexity of instruments and algorithms for
their detection and demonstrates the value in targeting a small
number of compounds for analysis.
In summary, pumped sampling onto TD tubes is an
effective method for the quantiﬁcation of fecal VOCs. Marked
differences in VOC concentrations were observed between
healthy controls and patients with GI disease, indicating the
potential for a rapid noninvasive diagnostic method. Of the
compounds determined, the ester and alcohol derivates of SCFA
show most promise for further development. Normalization of the
fecal VOC proﬁle following treatment suggests that this approach
could also be useful in monitoring progress of disease and the
effectiveness of therapy.
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